Send to printer »

Insight & Intelligence™ : Dec 9, 2013

Top 30 Venture Capital Firms of 2013

Who are the big spenders that help grease the wheels of biotech?

Just last week, a new biotech company called Juno Therapeutics was launched to the tune of $120 million in Series A financing. Where did this money come from? From the generous coffers of venture capital firms, including ARCH Venture Partners and the Alaska Permanent Fund. Such it is with every startup—venture capital is part of what makes new biotechs and biopharmas blossom. So, which VC companies invested money in those fields this year? Below is a list of 30 top venture capital firms, and broader financial firms that invest venture capital or other equity in early- to late-stage biotechnology and pharmaceutical companies, ranked by total capital under management or, for some firms, total active “committed” capital from funds in use.

This year’s list has been expanded to a top 30, in order to paint a more complete picture of biopharma venture investment and its key players—as well as to include the higher number of firms with funds totaling more than $1.1 billion compared with 2012.

The firms themselves are the sources of much of the information, though in some instances they have declined comment on news reports that they are raising additional capital; those instances are included in footnotes where the companies have not challenged the accuracy of the reports. In a handful of instances, figures and facts came from biographies of the firms’ principals available on the websites of investee companies and publicly available investor presentations posted online.

Interestingly, this year, five firms listed closed on new funds—less than the seven that did so last year, but a still-significant sign that more firms resumed raising new capital following years of near-standstill wrought by the 2007–09 recession.

#30. Enterprise Partners Venture Capital

City (cities) where offices are located: La Jolla, CA

Fund size and status: More than $1.1 billion under management across six funds

Current fund: $353 million EPVI, closed 2001

Current biopharma portfolio companies: Ascenta Therapeutics, Celladon, Celula, Complete Genomics

Typical investment range: Initial investment more typically ranges between $3 million and $10 million, with additional funds reserved for follow-on financings. Occasionally the partnership will invest as little as $300K in a seed stage venture. Preference for investing in California-based businesses

Year established: 1985

#29. Delphi Ventures

City (cities) where offices are located: Menlo Park, CA

Fund size and status: More than $1.1 billion in eight funds

Current fund: $300 million Delphi Ventures VIII, closed 2008

Current biopharma portfolio companies: Alder Biopharmaceuticals, Alexza Pharmaceuticals, Calithera Biosciences, Labcyte, NeurAxon, OncoMed Pharmaceuticals, ProActa, PTC Therapeutics, Relypsa

Typical investment range: Investment size ranges from $500,000 to $12 million per company

Year established: 1988

#28. Abingworth

City (cities) where offices are located: London; Menlo Park, CA; Waltham, MA

Fund size and status: More than $1.25 billion under management across nine funds

Most recent fund name: Abingworth Bioventures V, expanded to £392 million ($635 million) with the addition of £84 million ($136 million) raised in December 2008. The new monies were raised in an affiliated fund, Abingworth Bioventures V Co-Invest Growth Equity Fund. Firm also invests through Abingworth BioEquities, an open-ended fund and Abingworth’s first dedicated solely to investments in quoted stocks.1

Current biopharma portfolio companies: Ablynx, Algeta, Alnylam Pharmaceuticals, Amarin, Avedro, Avila Therapeutics, Avillon, Chiasma, Chroma Therapeutics, Clovis Oncology, Cytos Biotechnology, Dicerna Pharmceuticals, eFFECTOR Therapeutics, Epigenomics, EVF-Thyroid, GenSight Biologics, Hydra Biosciences, Intellikine, Labcyte, Magellan Biosciences, MD On-Line, Pathwork Diagnostics, Personalis, Portola Pharmaceuticals, PrimeraDx, Prosensa, SFJ Pharmaceuticals, Senseonics, Supernus Pharmaceuticals, Valeritas, Zogenix

Typical investment range: $20 million to $50 million per company; Monies may be invested over more than one round of financing. Investments across all stages of company development including early and late-stage venture, venture investments in public equities (VIPEs), growth equity and public markets

Year established: 1973

#27. Third Rock Ventures

City (cities) where offices are located: Boston and San Francisco

Fund size and status: More than $1.3 billion raised in three funds

Current fund: $516 million Fund III, which closed in March and was created to help launch up to 16 new companies focused on “disruptive” areas of science and medicine

Current biopharma portfolio companies: Ablexis, Afferent Pharmaceuticals, Agios Pharmaceuticals, Alcresta, Allena Pharmaceuticals, Alnara Pharmaceuticals, bluebirdbio, Blueprint Medicines, Constellation Pharmaceuticals, CytomX Therapeutics, Edimer, Eleven Biotherapeutics, Ember Therapeutics, Foundation Medicine, GlobalBlood Therapeutics, Igenica, JounceTherapeutics, Kala Pharmaceuticals, Lotus Tissue Repair, MyoKardia, PanOptica, Rhythm Pharmaceuticals, Sage Therapeutics, Topica Pharmaceuticals, WarpDriveBio, Zafgen

Typical investment range: Seeks to lead investing rounds, making an initial investment of up to $50 million, ideally at the formative stage of company development

Year established: 2007

#26. ARCH Venture Partners

City (cities) where offices are located: Chicago; Austin, TX; Seattle; San Francisco; Dublin

Fund size and status: Nearly $1.5 billion under management across seven funds

Current fund: $400 million ARCH Venture Fund VII, closed 2007

Current biopharma portfolio companies: Achaogen, Acylin Therapeutics, Agios Pharmaceuticals, Allozyne, Alnylam Pharmaceuticals, Array BioPharma, BIND Biosciences, bluebird bio, Chiasma, Ensemble Therapeutics, Fate Therapeutics, GenVec, Groove BioPharma, Hua Medicine, Ikaria, Illumina, ISB Accelerator, Kythera Biopharmaceuticals, Lycera, NeurogesX, Nura, Omeros, Oncofactor, Permeon Biologics, PhaseRx, Pulmatrix, Receptos, Sorbent Therapeutics, Syros Pharmaceuticals, Theraclone Sciences, VBI Vaccines, VentiRx Pharaceuticals, VLST, XenoPort, XORI

Typical investment range: Investment average or range per-company unavailable; firm applies "Innovation Investment" model that invests conservatively in a seed round and then leads and co-leads additional rounds to liquidity

Year established: 1986 as not-for-profit ARCH Development Corp. by University of Chicago

#25. Burrill & Co.

City (cities) where offices are located: San Francisco

Fund size and status: $1.5 billion under management across seven funds

Current fund: $505 million Burrill Capital Fund IV, closed for second time 2012

Current biopharma portfolio companies: Adlyfe, Catalyst Biosciences, Captaris Therapeutics, Cerca Inights Chromatin, LightSciences Oncology, Logical Therapeutics, Neos Therapeutics, Neurotech, Newbridge Pharmaceuticals, Nora Therapeutics, Odyssey Thera, Scynexis, Sentinext Therapeutics, Waterstone Pharmaceuticals, XDx

Typical investment range: Average funding: $5 million to $15 million over the life of a company. Most investments are expected to be in the startup through mezzanine stages. The largest number of investments are targeted to Series A and B rounds; the firm does invest in public entities. Principally invests in the United States and Europe, but has strategic interests globally

Year established: 1994

#24. Versant Ventures

City (cities) where offices are located: Menlo Park, CA; Newport Beach, CA; San Francisco; Basel, Switzerland; Vancouver, BC

Fund size and status: $1.6 billion in committed capital across four funds; disclosed plans in October 2013 to raise a $250 million fifth fund2

Current fund: $500 million Versant Venture Capital IV L.P., closed 2008

Current biopharma portfolio companies: 5AM Ventures, Achaogen, Audentes Therapeutics, Biotie Therapies, CymaBay Therapeutics (formerly Metabolex), Flap, Flexion Therapeutics, Fluidigm, Gensight Biologics, Groove Biopharma (formerly Mirina), Immune Design, Inception 1, Inception 2, Inception 3, Novira Therapeutics, OpGen, Panmira Pharmaceuticals, PhaseRx, Quanticel Pharmaceuticals, RuiYi, Spark Diagnostics, Theraclone Sciences, VLST.

Typical investment range: Initial investments have started at $250,000; total investments have been as large as $30 million

Year established: 1999

#23. HealthCare Ventures

City (cities) where offices are located: Cambridge, MA

Fund size and status: $1.6 billion under management across nine funds

Current fund: $250 million HealthCare Ventures IX L.P., closed 2010

Current biopharma portfolio companies: Aciex, Adheron Therapeutics, Anchor Therapeutics, Anexon, Apellis Pharmaceuticals, Apofore, BIKAM Pharmaceuticals, Catalyst Biosciences, Cleveland HeartLab, DecImmune Therapeutics, Dekkun, Galleon Pharmaceuticals, GITR, GlobeImmune, InfaCare Pharmaceutical, Mosaic Biosciences, nanoMR, PathoGenetix, PharmAthene, Promedior, ProteoStasis Therapeutics, Radius Health, Seahorse Bioscience, Shape Pharmaceuticals, Stemgent, Synovex, Tensha Therapeutics, TetraLogic Pharmaceuticals, Theraclone Sciences, Threshold Pharmaceuticals, Trevena, VaxInnate, Vaxxas, Xencor

Typical investment range: Up to $20 million total investment to achieve human proof-of-concept; invest predominantly in late preclinical and early clinical-stage, focused companies with the goal of advancing a single product to human proof-of-concept and exit through sale to a pharmaceutical or biotechnology company

Year established: 1985

#22. Bay City Capital

City (cities) where offices are located: San Francisco

Fund size and status: $1.6 billion in capital commitments across five general life sciences VC funds and three VC funds targeting specific geographies or sectors of the life sciences

Current general life-sci VC fund: $500 million Bay City Capital Fund V, closed in 2007. Most recent sector fund is Decheng Capital China Life Sciences USD Fund I

Current biopharma portfolio companies: Aciex, Aviir, BrainCells, Cadence Pharmaceuticals, Civitas Therapeutics, Conatus Pharmaceuticals, Cydan, CymaBay Therapeutics (formerly Metabolex), Dermira, Epizyme, Hyperion Therapeutics, Intarcia Therapeutics, Interleukin Genetics, ITC Nexus, Madrigal Pharmaceuticals, Merus Biopharmaceuticals, Nabsys, Poniard Pharmaceuticals, PharmAkea Therapeutics, Presidio Pharmaceuticals, PTC Therapeutics, ReSet Therapeutics, Sunesis, Vivaldi Biosciences

Typical investment range: Investment average or range per-company unavailable. Typically serves as lead or co-lead investor

Year established: 1997

#21. Advanced Technology Ventures

City (cities) where offices are located: Palo Alto, CA, and Boston

Fund size and status: $1.6 billion under management across eight funds

Current fund: $305 million ATV Fund VIII, closed 2007

Current biopharma portfolio companies: Acceleron Pharma, Calithera Biosciences, Catabasis Pharmaceuticals, Five Prime Therapeutics, Hydra Biosciences, Portola Pharmaceuticals, Second Genome, Thrasos Therapeutics, Verastem

Typical investment range: Investment average or range per-company unavailable

Year established: 1979

#20. SV Life Sciences

City (cities) where offices are located: Boston; San Francisco, CA; London

Fund size and status: Approximately $2 billion under management across five funds

Current fund: $524 million SV Life Sciences Fund V, closed 2010; fund includes $513 million, plus $11 million of co-investments committed by partners and individuals affiliated with SVLS

Current biopharma portfolio companies: Achillion Pharmaceuticals, Aderis Pharmaceuticals, Adimab, Affibody, Affinium Pharmaceuticals, Alantos Pharmaceuticals, Alba Therapeutics, Alinea Pharmaceuticals, Allocure, Allos Therapeutics, Antiva, Archemix, Arsanis Biosciences, Atopix Therapeutics/Oxagen, Autifony Therapeutics, Auxilium, Avera Pharmaceuticals, Avitide, Axys, Bicycle Therapeutics, BioClinica, Calchan Holdings, Catabasis Pharmaceuticals, Celerion, Cellzome, Convergence Pharmaceuticals, Coral Therapeutics, Cyterix Pharmaceuticals, Delenex Therapeutics, Dynogen Pharmaceuticals, EUSA Pharma, Good Start Genetics, Ikano Therapeutics, Imagen Biotech, Itero Biopharmaceuticals, Juvaris Biotherapeutics, KalVista Pharmaceuticals, Karus Therapeutics, Link Medicine, Logical Therapeutics, Lux Biosciences, Metris Therapeutics, Micromet, Mpex Pharmaceuticals, NeurogesX, Neurotech, NKT Therapeutics, Oncoethix, Ophthotech, PanOptica, Rempex Pharmaceuticals, Shire Pharmaceuticals, Sutro Biopharma, TopiVert, Trine Pharmaceuticals, Vantia Pharmaceuticals, Vernalis, X2-Pharma

Typical investment range: Firm primarily invests between $1 million and $40 million in North American and European companies, but will consider “innovative” investments in other regions

Year established: Established 1993 as Schroder Ventures Life Sciences, part of the Schroder Ventures Group. SVLS became independent of the Schroder Ventures Group in 2001, and changed its name in 2005

#19. Alta Partners

City (cities) where offices are located: San Francisco

Fund size and status: $2 billion under management across eight funds

Current fund: $500 million Alta Partners VIII, a first stage-independent life sciences fund closed 2006

Current biopharma portfolio companies: 7TM Pharma, Ablynx, AcelRx Pharmaceuticals, Achaogen, Aegerion Pharmaceuticals, Aerie Pharmaceuticals, Aerovance, Alba Therapeutics, Allakos, Applied Genetic Technologies (AGTC), Astex Pharmaceuticals, aTyr Pharma, Azelon Pharmaceuticals, Cara Therapeutics, Ceregene, Cerenis Therapeutics, ChemoCentryx, Chimerix, Corcept Therapeutics, CymaBay Therapeutics (formerly Metabolex), Cytokinetics, DiscoveRx, Esperion Therapeutics, Excaliard Pharmaceuticals, Genedata, Immune Design, Intarcia Therapeutics, Kiadis Pharma, Kite Pharma, Lithera, Lumena Pharmaceuticals, MacroGenics, Nereus Pharmaceuticals, Pathwork Diagnostics, Portola Pharmaceuticals, Proacta Therapeutics, Prolacta Bioscience, Scynexis, Silence Therapeutics, Sonexa Therapeutics, Sunesis Pharmaceuticals, Sutro Biopharma, Threshold Pharmaceuticals, Trevena, Veloxis, ViroBay, VitrOmics

Typical investment range: Investment average or range per-company unavailable

Year established: 1996

#18. Third Security

City (cities) where offices are located: Radford, VA; San Francisco; Palm Beach, FL

Fund size and status: More than $2 billion under management through nine affiliated investment funds, consisting of seven New River Management Funds and two regional funds

Current New River Management Funds: $120 million New River Management VII, closed 2012; $15 million Valleys’ Ventures, launched May 2013 to invest in companies that intend to commence operations in, or are willing to relocate to an area within 100 miles of Montgomery, Roanoke or Botetourt counties of southwestern Virginia

Current biopharma portfolio companies: AmpliPhi Biosciences, Biolife Cell Bank, Fibrocell Science, Halozyme Therapeutics, Intrexon, Oragenics, Soligenix, Synthetic Biologics

Typical investment range: Investment average or range per-company unavailable

Year established: 1999

#17. Mohr Davidow Ventures

City (cities) where offices are located: Menlo Park, CA

Fund size and status: More than $2 billion under management in nine funds

Most recent fund: $670 million MDV IX fund, first closed 2007 at $580 million. In January 2013, the firm reduced its MDV VII fund to $450 million from $670 million; Fund VII was reduced once before, in 2012, from its initial $840 million close

Current biopharma portfolio companies: Adamas, CardioDx, Crescendo Bioscience, Pacific Biosciences, Personalis, RainDance Technologies, Tethys Bioscience

Typical investment range: Investment average or range per-company unavailable

Year established: 1983

#16. Frazier Healthcare

City (cities) where offices are located: Seattle and Menlo Park, CA

Fund size and status: More than $2 billion under management across seven funds

Current fund: $377 million Frazier Healthcare VII, closed September 2013

Current biopharma portfolio companies: Achaogen, Alcresta, Allena Pharmaceuticals, Amicus Therapeutics, Anaptys, Attercor, Cadence Pharmaceuticals, Chimerix, Collegium Pharmaceutical, Portola Pharmaceuticals, QuatRx, Rempex Pharmaceuticals, Semnur Pharmaceuticals, Silvergate Pharmaceuticals, Tobira Therapeutics, VentiRx Pharmaceuticals

Typical investment range: Growth equity investment commitments have ranged between $20 million and $50 million; venture investment average or range per-company unavailable. Since 2002, firm has been founding investor in more than 50% of its biopharma portfolio companies, and lead investor in more than 75% of these companies.

Year established: 1991

#15. Venrock

City (cities) where offices are located: Cambridge, MA; New York; Palo Alto, CA

Fund size and status: $2.2 billion under management across six funds

Current fund: $350 million Venrock VI, closed 2010

Current biopharma portfolio companies: Acceleron Pharma, Achaogen, Anacor Pharmaceuticals, Ariosa Diagnostics, AVEO Pharma, Celladon, Cerulean, Constellation Pharmaceuticals, CymaBay Therapeutics (formerly Metabolex), Fate Therapeutics, Hua Medicine, Ikaria, Infinity Pharmaceuticals, Intarcia Therapeutics, Ironwood Pharma, Pathwork Diagnostics, QuatRx, Receptos, Vitae Pharmaceuticals

Typical investment range: Investment average or range per-company unavailable

Year established: 1969

#14. Morgenthaler Ventures — Life Sciences Team

City (cities) where offices are located: Palo Alto, CA; Boston; Boulder, CO

Fund size and status: $2.5 billion under management

Current fund: $400 million Fund IX, closed 2008 and used in part for investment in life-sciences companies. The general partners of the Life Sciences team and Advanced Technology Ventures joined investors from both in 2012 to create a new firm, Lightstone Ventures, which has declined comment on a news report that it is close to raising $150 million.3

Current biopharma portfolio companies: Calithera Biosciences, Catalyst Biosciences, Elcelyx Therapeutics, Galleon Pharmaceuticals, GlobeImmune, Mosaic Biosciences, OncoMed Pharmaceuticals, Orexigen, Principia Biopharma, Promedior Pharmaceuticals, Ra Pharmaceuticals, Replidyne, Ribozyme Pharmaceuticals, Scioderm, Stemgent, Threshold Pharmaceutical, Tragara Pharmaceuticals, Trellis Bioscience, Vical

Typical investment range: Between $12 million and $15 million total investment per company over several rounds; predominantly Series A, but open to later-stage investments: “In biotech, we look for multi-product platforms, or targeted therapies, that can achieve clinical proof of principle within five years.”

Year established: 1968

#13. Essex Woodlands Health Ventures

City (cities) where offices are located: Palo Alto, CA; New York; Houston; London; Shanghai

Fund size and status: More than $2.5 billion under management across eight funds

Current fund: $900 million Fund VIII, closed 2009; firm declined comment in October on a published report that it was seeking capital from investors for $750 million ninth fund4

Current biopharma portfolio companies: Acura Pharmaceuticals (formerly Halsey Drug), Biotoscana, Catalyst Biosciences, Chroma Therapeutics, Corium (formerly Stratagent Life Sciences), Curis (formerly Reprogenesis), Elusis Therapeutics (formerly E-Site Therapeutics), EUSA Pharma, Horizon Pharma (formerly Horizon Therapeutics), IntegenX, LightSciences Oncology, Medicinova, Molecular Partners, Open Monoclonal Technology, Palatin, Palmetto Pharmaceuticals (formerly eNOS Pharmaceuticals), Parexel, PreCision Dermatology, ProteinSimple, Revance Therapeutics (formerly Essentia BioSystems), Serene Oncology, Symphogen, Xanodyne Pharmaceuticals (formerly Integrity Pharmaceuticals), Repros Therapeutics (formerly Zonagen), Ziopharm Oncology

Typical investment range: Venture investment average or range per-company unavailable; growth equity investments typically range from $20 million to $60 million, with the firm capable of investing up to $100 million per deal

Year established: 1985

#12. MPM Capital

City (cities) where offices are located: Boston; South San Francisco, CA; Munich; Gainesville, FL; Kansas City, KS

Fund size and status: More than $2.6 billion committed capital under management across five funds

Current fund: Approximately $300 million MPM BioVentures V L.P., closed 2010

Current biopharma portfolio companies: Aires Pharmaceuticals, Allozyne, Amphivena Therapeutics, Anthera Pharmaceuticals, Aveo Oncology, Celladon, Ceregene, Chiasma, Colucid Pharmaceuticals, Conatus Pharmaceuticals, Costin Pharmaceuticals, EKR Therapeutics, Epigenomics, Epizyme, Idenix Pharmaceuticals, iPierian, Kalidex Pharmaceuticals, KaloBios Pharmaceuticals, Macrogenics, Mitokyne, NeuroTherapeutics Pharma, Oxagen, Pacira Pharmaceuticals, Pharmathene, Poniard Pharmaceuticals, Portola Pharmaceuticals, Proteon Therapeutics, QuatRx Pharmaceuticals, Radius Health, Rhythm Pharmaceuticals, Selexys Pharmaceuticals, Sideris Pharmaceuticals, Solasia Pharma, Swedish Orphan BioVitrum, Syndax Pharmaceuticals, Theraclone Sciences, Verastem, VLST, Xanodyne Pharmaceuticals, Zalicus (formerly CombinatoRx)

Typical investment range: Investment average or range per-company unavailable

Year established: 1996

#11. Domain Associates

City (cities) where offices are located: Princeton, NJ, and San Diego

Fund size and status: More than $2.7 billion under management across eight funds

Current fund: $500 million Domain Partners VIII, closed 2009

Current biopharma portfolio companies: Achaogen, Achillion Pharmaceuticals, Adynxx, Afferent Pharmaceuticals, Aldexa Therapeutics, Alimera Sciences, Applied Proteomics, Ariosa Diagnostics, Ascenta Therapeutics, Asmacure, Astute Medical, Atara Biotherapeutics, aTyr Pharma, BioNano Genomics, Cadence Pharmaceuticals, Cantex Pharmaceuticals, Celator Pharmaceuticals, Clovis Oncology, CoDa Therapeutics, CoLucid Pharmaceuticals, Corridor Pharmaceuticals, Dicerna Pharmaceuticals, Domain Elite Holdings, Domain Russia Investments, Durata Therapeutics, Eddingpharm International Holdings, Epic Sciences, Esperion Therapeutics, Evoke Pharma, Five Prime Therapeutics, IntegenX, Lithera, Marinus Pharmaceuticals, Meritage Pharma, NovaDigm Therapeutics, Ocera Therapeutics, Oraya Therapeutics, Orexigen Therapeutics, Otonomy, ProteinSimple, Regardo Biosciences, Sera Prognostics, Sonexa Therapeutics, Syndax Pharmaceuticals, Tobira Therapeutics, Tragara Pharmaceuticals, VentiRx Pharmaceuticals, Veracyte, Zogenix

Typical investment range: Investment average or range per-company unavailable

Year established: 1985

#10. InterWest Partners

City (cities) where offices are located: Menlo Park, CA

Fund size and status: $2.8 billion under management across 10 funds

Current fund: $650 million IW X Fund, closed 2008

Current biopharma portfolio companies: Applied Genetic Technologies (AGTC), Alvine Pharmaceuticals, Amplimmune, Arcion Therapeutics, Biomimetic, Carbylan Biosurgery, Cebix, Drais Pharmaceuticals, Eiger Pharmaceuticals, Fluidigm, Integrated Diagnostics (Indi), Lycera, MacroGenics, Ocera Therapeutics, On Demand Therapeutics, PrimeraDx, QuatRx Pharmaceuticals, RadioRx, Sera Prognostics, Tesaro, Transcept Pharmaceuticals, Trius Therapeutics, USDS, Xenon Pharmaceuticals

Typical investment range: Average per company investment is $10 million to $15 million

Year established: 1979

#9. Atlas Venture

City (cities) where offices are located: Cambridge, MA

Fund size and status: More than $3 billion in committed capital across nine funds; about $1 billion in current active assets under management, including $265 million Atlas Venture IX, closed April 2013

Current biopharma portfolio companies: Achilion Pharmaceuticals, Annovation Biopharma, ARCA Biopharma, Arteaus Therapeutics, Bicycle Therapeutics, CoStim Pharmaceuticals, Egalet, F-star, Harbour Antibodies, Horizon Pharma, Infacare Pharmaceutical, JenaValve, MiRagen Therapeutics, Mnemosyne Pharmaceuticals, Nimbus Discovery, ProtAffin Biotechnologies, RaNA Therapeutics, Rodin Therapeutics, SciClone Pharmaceuticals, Vitae Pharmaceuticals, Zafgen

Typical investment range: Typical initial investment of $500,000 to $5 million: “Some of our investments are as little as $100K, but we can also follow our portfolio companies through IPO, as in the case of Isilon, where we invested $24M for 24% of the business,” the firm states on its website.

Year established: 1986

#8. Index Ventures

City (cities) where offices are located: Geneva, London, San Francisco, and St. Helier, Jersey

Fund size and status: $3.25 billion in total committed capital across mixed and dedicated funds, of which about $1 billion is dedicated to life sciences

Current fund: $200 million Index Life Sciences VI, closed 2012

Current biopharma portfolio companies: CoMentis, Egalet, Fast Forward, GenSight Biologics, GlycoVaxyn, Levicept, Minerva, Molecular Partners, Novocure, OncoEthix, Sequenta, Versartis, XO1

Typical investment range: $50,000 to $25 million per company

Year established: 1996

#7. Canaan Partners

City (cities) where offices are located: Menlo Park, CA; Westport, CT; New York; Gurgaon, India; Herzliya Pituach, Israel

Fund size and status: $3.4 billion under management across nine funds

Current fund: $600 million Canaan Partners IX, closed 2012

Current biopharma portfolio companies: Adlyfe, ALDEA Pharmaceuticals, Amicus Therapeutics, Apieron, Centocor, Chimerix, Civitas Therapeutics, Cylex, CytomX Therapeutics, Data Sciences International, Dermira, DexCom, Durata Therapeutics, GenVec, Kalidex Pharmaceuticals, Liquidia Technologies, Marinus Pharmaceuticals, Matrix Pharma, Novira Therapeutics, Phylogix, Pozen, Sopherion, Theraclone Sciences, Tobira Therapeutics, VaxInnate, Zalicus (formerly CombinatoRx)

Typical investment range: Investment average or range per-company unavailable

Year established: 1987

#6. Highland Capital Partners

City (cities) where offices are located: Cambridge, MA; Menlo Park, CA; Shanghai; London; and Geneva

Fund size and status: Nearly $3.5 billion under management across 11 funds, the most recently announced being its $25 million Leap Fund™, designed “to support entrepreneurs and companies that are developing breakthrough experiences to solve human scale problems” in sectors that include big data, education, healthcare IT, and security.5 Company has not confirmed a news report that an additional fund, Highland Capital Partners IX L.P., closed last month at $400 million6; Highland disclosed it was seeking to raise that amount in an April 16 filing with the U.S. Securities and Exchange Commission7

Current biopharma portfolio companies: Aveo Oncology, Hyperion Therapeutics, iPierian, OpGen

Typical investment range: Investment average or range per-company unavailable

Year established: 1988

#5. Polaris Venture Partners

City (cities) where offices are located: Waltham, MA; San Francisco; Dublin; Boston office “coming soon”. Also, @dogpatchlabs locations in Cambridge, MA, and Dublin for communities of biotechnology and technology startups

Fund size and status: $3.5 billion under management across six funds

Current fund: $375 million Polaris Venture Partners VI, closed 2010

Current biopharma portfolio companies: Acceleron Pharma, Adimab, Alimera Sciences, Arsanis Biosciences, aTyr Pharma, BIND Biosciences, Calorics Pharmaceuticals, Cerulean Pharma, Fate Therapeutics, Genocea Biosciences, Hydra Biosciences, Ironwood, Kala Pharmaceuticals, Ocular Therapeutix, Promedior, Pulmatrix, Receptos, Selecta Biosciences, Trevena, Visterra, Xtuit Pharmaceuticals

Typical investment range: Investment average or range per-company unavailable

Year established: 1996

#4. Bessemer Venture Partners

City (cities) where offices are located: Cambridge, MA; New York; Menlo Park, CA; Sao Paulo, Brazil; Herzliya Pituach, Israel; Mumbai

Fund size and status: More than $4 billion under management across eight funds

Current fund: $1.6 billion Bessemer Venture Partners VIII, closed 2011

Current biopharma portfolio companies: Acceleron Pharma, AffyMax, Allena Pharmaceuticals, Arris Pharmaceuticals, Cerulean Pharma, Insmed, On-Q-ity, Oxagen, Proteon Therapeutics, Verastem

Typical investment range: Investment average or range per-company unavailable

Year established: 1911

#3. OrbiMed Advisors

City (cities) where offices are located: New York; San Francisco; Shanghai; Mumbai; Herzliya, Israel

Fund size and status: More than $8 billion under management in five public funds, as well as private equity funds in North America/Europe, Asia, and Israel; and a Royalty Opportunities Fund launched 2011 to invest in healthcare royalty streams

Current fund: $735 million OrbiMed Private Investments V, closed October 2013

Current biopharma portfolio companies: Acceleron Pharma, Adimab, Aerocrine, Affimed, Amarin, Ambit Biosciences, Anthera, arGEN-X, ARMO Biosciences, Arsanis Biosciences, Arteaus, Audentes Therapeutics, Avitide, Bharat Serums and Vaccines, Biodel, BioLineRx, Cardioxyl, cCAM Biotherapeutics, Cerenis Therapeutics, Cleave Biosciences, Durata Therapeutics, Eddingpharm, Good Start Genetics, Igenica, Intercept Pharmaceuticals, Loxo Oncology, MacroGenics, Mirati Therapeutics, Natera, Otic Pharma, Otonomy, OxOnc Development, PharmAbcine, Pieris, Principia Biopharma, RDD Pharma, Receptos, Relypsa, Rempex Pharmaceuticals, Response BioMedical, Roka BioScience, Selecta Biosciences, Singulex, Shasun, Supernus Pharmaceuticals, Waterstone Pharmaceuticals

Typical investment range: OrbiMed Private Investments V is expected to invest in about 30 portfolio companies, “in amounts generally ranging from $10 million to $50 million”

Year established: 1989

#2. Kleiner Perkins Caufield & Byers

City (cities) where offices are located: Menlo Park, CA; San Francisco; Beijing; Shanghai

Fund size and status: More than $7 billion in assets under management across 15 funds

Current fund: $525 million KPCB 15, closed 2012

Current biopharma portfolio companies: 3-V Biosciences, Athena Neurosciences, Auxogyn, AwarePoint, BioCryst Pharmaceuticals, Biosite, CardioDx, Cardium Therapeutics, Chiral Quest, Codon Devices, Corixa, Corthera, Crescendo Bioscience, Elcelyx, Emdeon, EntreMed, Epizyme, Essence Healthcare, FivePrime Therapeutics, Focal, Foundation Medicine, Gen-Probe, Genentech, Genomic Health, GenScript, iPierian, ITC, Kindstar Global, Microcide Pharmaceuticals, Navigenics, Neurocrine Biosciences, Nexus Dx, Nodality, Novavax, Oculeve, Onyx Pharmaceuticals, Orexigen, Pacific Biosciences, Pharmacopeia, Pharmacyclics, Rapid Micro Biosystems, Tesaro, Tethys, Trius Therapeutics, True North Therapeutics, Veracyte, Xcellerex, XDx

Typical investment range: Seed investments typically range from $100,000 to $1 million; early-stage, from $1 million to $10 million; growth-stage, from $10 million to $75 million

Year established: 1972

#1. New Enterprise Associates (NEA)

City (cities) where offices are located: On November 14, NEA announced opening of its newest office in Cambridge, MA, joining existing offices in Menlo Park, CA; Chevy Chase, MD; Timonium, MD; New York, Chicago; as well as affiliate operations in Beijing; Shanghai; Bangalore; Mumbai.

Fund size and status: Approximately $13 billion in committed capital across 14 funds

Current fund: $2.6 billion New Enterprise Associates 14 L.P., closed 2012

Current biopharma portfolio companies: 3-V Biosciences, Acadia Pharmaceuticals, Aciex, Alimera Sciences, Amicus Therapeutics, Ardelyx, Blend Therapeutics, BrainCells, Cadence Pharmaceuticals, Cardioxyl Pharmaceuticals, Cleave Biosciences, Clovis Oncology, Cydan, Dermira, Edimer Pharmaceuticals, Epizyme, Galera Therapeutics, GlycoMimetics, Hydra Biosciences, Hyperion Therapeutics, Intarcia Therapeutics, Liquidia Technologies, Mersana Therapeutics, Mirna Therapeutics, Nexchem, Novast Holdings, Omthera Pharmaceuticals, Predictive Biosciences, Prosensa, Proteostasis Therapeutics, Psyadon Pharmaceuticals, Ra Pharma, Rhythm Pharmaceuticals, Rigel Pharmaceuticals, Roka Bioscience, Satori Pharmaceuticals, Sunesis Pharmaceuticals, Supernus Pharmaceuticals, Targacept, Tesaro, Theravance, Transcept Pharmaceuticals, Trevena, Vitae Pharmaceuticals, Zyngenia

Typical investment range: Investment average or range per-company unavailable

Year established: 1977